The role of Kynurenine-Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) axis in migraine pathophysiology and therapy.

Migraine is a common headache disorder, but its exact causes remain unclear. Researchers have traditionally focused on serotonin, but new studies highlight a different pathway. This pathway involves tryptophan metabolism, specifically the Kynurenine pathway (KP). The KP helps regulate glutamatergic neurotransmission and produces both protective and harmful metabolites. One important metabolite is kynurenic acid (KYNA), which blocks certain receptors in the brain. Evidence suggests that KYNA significantly influences migraine attacks. Preclinical studies show that KYNA and similar compounds can reduce migraine-related issues. Additionally, previous clinical research indicates that migraine patients have an imbalance in these protective and harmful metabolites. Understanding this imbalance could lead to new treatment options. By exploring the Kynurenine-PACAP axis, researchers hope to uncover more about migraine mechanisms and develop better therapies for patients suffering from this debilitating condition. Clinical relevance: This research suggests that targeting the Kynurenine pathway may improve migraine treatments.